-
Innovation Ranking
NewInnovation Ranking – Seres Therapeutics Inc
Seres Therapeutics Inc (Seres) is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’s lead development candidate, SER-109 is an oral microbiome therapeutic and bacterial spore ecology. Seres’ SER-287 is an oral therapy for the treatment of ulcerative colitis, an inflammatory bowel disease. Its development programs also include SER-301 and SER-155,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SER-155 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SER-155 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SER-155 in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
Klebsiella Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Klebsiella Infections - Drugs In Development, 2023’, provides an overview of the Klebsiella Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Klebsiella Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Klebsiella pneumoniae Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Klebsiella pneumoniae Infections - Drugs In Development, 2023’, provides an overview of the Klebsiella pneumoniae Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leukocyte Disorders (White Blood Cell Disorders) - Drugs In Development, 2023’, provides an overview of the Leukocyte Disorders (White Blood Cell Disorders) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leukocyte Disorders (White Blood Cell Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Graft Versus Host Disease (GVHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Drugs In Development, 2023’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Bone Marrow Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Thematic Analysis
State of the Biopharmaceutical Industry in 2024 – Thematic Intelligence
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you in: Examining the current attitudes of business leaders toward the emerging trends impacting the biopharmaceutical industry in the next 12 months. Benchmarking the impact of major themes on the biopharmaceutical industry in 2024, including emerging technologies, regulatory trends, macroeconomic trends, and industry trends. Identifying the most impactful anticipated regulatory approvals and drug launches in the industry in 2024, learning about top-selling drugs (2023 vs 2024), and obtaining...
-
Product Insights
NewNet Present Value Model: Seres Therapeutics Inc’s SER-109
Empower your strategies with our Net Present Value Model: Seres Therapeutics Inc's SER-109 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.